Production and characterization of murine models of classic and intermediate maple syrup urine disease.
BACKGROUND
Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism caused by a deficiency of branched-chain keto acid dehydrogenase. MSUD has several clinical phenotypes depending on the degree of enzyme deficiency. Current treatments are not satisfactory and require new approaches to combat this disease. A major hurdle in developing new treatments has been the lack of a suitable animal model.


METHODS
To create a murine model of classic MSUD, we used gene targeting and embryonic stem cell technologies to create a mouse line that lacked a functional E2 subunit gene of branched-chain keto acid dehydrogenase. To create a murine model of intermediate MSUD, we used transgenic technology to express a human E2 cDNA on the knockout background. Mice of both models were characterized at the molecular, biochemical, and whole animal levels.


RESULTS
By disrupting the E2 subunit gene of branched-chain keto acid dehydrogenase, we created a gene knockout mouse model of classic MSUD. The homozygous knockout mice lacked branched-chain keto acid dehydrogenase activity, E2 immunoreactivity, and had a 3-fold increase in circulating branched-chain amino acids. These metabolic derangements resulted in neonatal lethality. Transgenic expression of a human E2 cDNA in the liver of the E2 knockout animals produced a model of intermediate MSUD. Branched-chain keto acid dehydrogenase activity was 5-6% of normal and was sufficient to allow survival, but was insufficient to normalize circulating branched-chain amino acids levels, which were intermediate between wildtype and the classic MSUD mouse model.


CONCLUSIONS
These mice represent important animal models that closely approximate the phenotype of humans with the classic and intermediate forms of MSUD. These animals provide useful models to further characterize the pathogenesis of MSUD, as well as models to test novel therapeutic strategies, such as gene and cellular therapies, to treat this devastating metabolic disease.
Homanics
Gregg E
GE
Departments of Anesthesiology and Pharmacology, University of Pittsburgh, Pittsburgh, PA 15261, USA. homanicsge@anes.upmc.edu
Skvorak
Kristen
K
Ferguson
Carolyn
C
Watkins
Simon
S
Paul
Harbhajan S
HS
D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) / Q000378:metabolism; D000217:Acyltransferases / Q000032:analysis / Q000235:genetics; D000597:Amino Acids, Branched-Chain / Q000097:blood / Q000652:urine; D000818:Animals; D004195:Disease Models, Animal; D018390:Gene Targeting; D006801:Humans; D008375:Maple Syrup Urine Disease / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D051379:Mice / Q000235:genetics*; D018345:Mice, Knockout; D008822:Mice, Transgenic
D000597:Amino Acids, Branched-Chain; D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D000217:Acyltransferases; C033588:dihydrolipoamide acyltransferase